Kronos Bio, Inc. announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company?s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. The company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | +2.04% | -0.99% | -20.00% |
Mar. 21 | Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M | MT |
Mar. 21 | Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 60.1M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio Plans to Reduction in Force